Clinical Trials Logo
  1. Home
  2. Alpha1-antitrypsin Deficiency
  3. NCT02525861

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

Alpha1-antitrypsin Deficiency Clinical Trial

Official title:
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects

Clinical Trial Summary

The purpose of the study is 2-fold: (1) to evaluate the safety and potential immunogenicity of GLASSIA following intravenous (IV) administration via in-line filtration; and (2) to assess the effects of GLASSIA augmentation therapy on the levels of A1PI and various biomarkers in the epithelial lining fluid (ELF) following intravenous (IV) administration at a dosage of 60 milligrams per kilogram (mg/kg) Body weight (BW)/week active alpha1-proteinase inhibitor (A1PI) protein for 25 weeks in participants with emphysema due to congenital A1PI deficiency.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02525861
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date March 8, 2016
Completion date July 29, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT02282527 - A Study to Assess Safety and PK of Liquid Alpha1-Proteinase Inhibitor (Human) in Treating Alpha1-Antitrypsin Deficiency Phase 2/Phase 3
Terminated NCT02722304 - Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency Phase 3
Withdrawn NCT04440488 - ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study Phase 4
Recruiting NCT05677971 - Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Phase 3
Recruiting NCT06165341 - Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) Phase 3
Completed NCT00157092 - Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency Phase 1/Phase 2
Terminated NCT00313144 - Aralast alpha1-proteinase Inhibitor Surveillance Study Phase 4
Completed NCT01651351 - GLASSIA Infusion Rate Study Phase 4
Completed NCT02870348 - Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) Phase 1/Phase 2
Completed NCT02870309 - Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency Phase 1/Phase 2
Completed NCT04474197 - Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype Phase 2
Completed NCT00161707 - Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency Phase 1/Phase 2
Withdrawn NCT05466747 - A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema Phase 4
Enrolling by invitation NCT05899673 - An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease Phase 3
Recruiting NCT04722887 - A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency Phase 1/Phase 2
Recruiting NCT02929940 - Liver Disease in Patients With alpha1-antitrypsin Deficiency N/A